US OptionsDetailed Quotes
BMEA241220C10000
- 0.05
- 0.000.00%
15min DelayTrading Dec 18 14:58 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume1.55K Open Interest10.00Strike Price0.00Turnover905.97%IV139.86%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0659Delta0.0617Gamma83.80Leverage Ratio-0.0500Theta0.0000Rho5.53Eff Leverage0.0003Vega
Biomea Fusion Stock Discussion
Sign in to post a comment
$Biomea Fusion (BMEA.US)$ is -without doubts- burning money at a super high speed.
Yet all the analysts are giving target price from a low 11$ to a 50/60 and above.
What's your take?
Yet all the analysts are giving target price from a low 11$ to a 50/60 and above.
What's your take?
7
$Biomea Fusion (BMEA.US)$ expecting offering for ATM after the next catalyst on March 2025. Monthly cash burning up to 10mil and should deplete by April / May 2025.
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 ...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 ...
58
18
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Biomea Fusion (BMEA.US)$ Reuters· 5 mins ago
Biomea Fusion Inc - Icovamenib Meets Primary Endpoint With Significant Reduction in Hba1C
Biomea Fusion Inc - Icovamenib Meets Primary Endpoint With Significant Reduction in Hba1C
3
$Biomea Fusion (BMEA.US)$
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Tuesday, 17th December at 8:10 am
• Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
• Best response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placeb...
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Tuesday, 17th December at 8:10 am
• Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
• Best response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placeb...
1
$Biomea Fusion (BMEA.US)$ I see that some must be anticipating that the data release today is going to be positive! Hehehe![]()
3
5
No comment yet
The Only Way is Up : Give it some time for phase 3
Shroomie The Only Way is Up : it takes like a year for phase 3 lol
Shroomie : it will drop and keep dropping
Shroomie : you're welcome
Shroomie : phase 3 takes a long time. in the meantime, the cash burn is insane, future big dilution coming.. knocking the price lower and lower
View more comments...